Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Breast Neoplasms 3502Neoplasms 2744Prostatic Neoplasms 1585Colorectal Neoplasms 1248Lung Neoplasms 1190Motor Activity 768Head and Neck Neoplasms 621Pancreatic Neoplasms 601Colonic Neoplasms 586Uterine Cervical Neoplasms 567Carcinoma, Non-Small-Cell Lung 561Carcinoma, Hepatocellular 561Rectal Neoplasms 516Stomach Neoplasms 493Brain Neoplasms 439Ovarian Neoplasms 401Anxiety Disorders 401Pain 377Esophageal Neoplasms 347Polycystic Ovary Syndrome 341Neoplasm Metastasis 340Fatigue 325Urinary Bladder Neoplasms 315Precursor Cell Lymphoblastic Leukemia-Lymphoma 303Melanoma 299Depression 286Multiple Myeloma 283Endometrial Neoplasms 264Lymphoma 258Hematologic Neoplasms 251

Interventions

lenvatinib 1cabozantinib 1Restraint, Physical 1Absorptiometry, Photon 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × OTHER × Paraganglioma, Extra-Adrenal × Clear all
NCT02592356 2024-03-05

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

M.D. Anderson Cancer Center

Phase NA Completed
23 enrolled
CNSEndocrine

Paraganglioma, Extra-Adrenal, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡